natgillin/translations-raw huggingface dataset:
There was no relevant difference in the number of patients with severe hypertension showing a relevant BP lowering effect during the first 4 weeks. 
Pomembnih razlik v številu bolnikov s hudo hipertenzijo, pri katerih je bilo v prvih štirih tednih opaziti učinek pomembnega znižanja krvnega tlaka, ni bilo.
• Hypersensitivity to losartan, sulphonamide-derived substances (as hydrochlorothiazide) or to any of the excipients 
• Preobčutljivost za losartan, derivate sulfonamidov (kot je hidroklorotiazid) ali katerokoli pomožno snov.
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium. 
Kot pri drugih zdravilih, ki zavirajo angiotenzin II ali njegove učinke, lahko sočasna uporaba diuretikov, ki varčujejo kalij (npr. spironolaktona, triamterena, amilorida), dodatkov kalija ali nadomestkov soli, ki vsebujejo kalij, povzroči zvišanje vrednosti kalija v serumu.
When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. 
Po najmanj 24-urnem spremljanju plazemske koncentracije so opazili spremenljiv plazemski razpolovni čas od 5,6 do 14,8 ur.
Marked hypercalcemia may be evidence of hidden hyperparathyroidism. 
Znatna hiperkalciemija je lahko pokazatelj skritega hiperparatiroidizma.
Limited data are available in regard to overdosage in humans. 
Podatkov o prevelikem odmerjanju pri ljudeh je malo.
Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. 
Hidroklorotiazid se ne presnavlja, ampak se hitro izloči skozi ledvice.
Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) Possible increased responsiveness to the muscle relaxant. 
Nedepolarizirajoči relaksanti skeletnih mišic (npr. tubokurarin) Možna je povečana odzivnost na mišični relaksant.
Suggested measures include induction of emesis if ingestion is recent, and correction of dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. 
Priporočeni ukrepi zajemajo izzvanje bruhanja, če je bilo zdravilo zaužito pred kratkim, ter korekcijo dehidracije, elektrolitskega neravnovesja, hepatične kome in hipotenzije po ustaljenih metodah.
It is also important for your doctor to know if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers, drugs for treatment of fungal infections, or arthritis medicines, resins used for high cholesterol, such as colestyramine, medicines which relax your muscles, sleeping tablets; opioid medicines such as morphine , ‘pressor amines' such as adrenaline or other drugs from the same group; (oral agents for diabetes or insulins). 
Pomembno je, da vaš zdravnik ve, če jemljete še druga zdravila za zniževanje krvnega tlaka, steroide, zdravila za zdravljenje raka, zdravila za bolečine, zdravila za zdravljenje glivičnih okužb, zdravila za artritis, smole za zdravljenje povišanega holesterola, kot je holestiramin, zdravila za sprostitev mišic, uspavala, opioidna zdravila kot je morfin, presorni amini, kot je adrenalin ali druga zdravila iz iste skupine.
In patients receiving thiazides, hypersensitivity reactions may occur with or without a history of allergy or bronchial asthma. 
Pri bolnikih, ki dobivajo tiazide, se lahko pojavijo preobčutljivostne reakcije ne glede na to, ali so kdaj imeli alergije ali bronhialno astmo, ali ne.
Therefore, the plasma concentrations of potassium and creatinine clearance values should be closely monitored; especially patients with heart failure and a creatinine clearance between 30-50 ml/ min should be closely monitored. 
Zato je treba pozorno spremljati plazemske koncentracije kalija ter kreatininski očistek, še posebej pri bolnikih s srčnim popuščanjem in kreatininskim očistkom 3050 ml/min.
Patients should be observed for clinical signs of fluid or electrolyte imbalance, e.g., volume depletion, hyponatremia, hypochloremic alkalosis, hypomagnesemia or hypokalemia which may occur during intercurrent diarrhea or vomiting. 
Bolnike je treba nadzorovati zaradi morebitnega pojava kliničnih znakov neravnovesja tekočin ali elektrolitov, npr. zmanjšanja volumna, hiponatriemije, hipokloremične alkaloze, hipomagneziemije ali hipokaliemije, ki se lahko pojavijo med vmesno diarejo ali bruhanjem.
• if you are allergic (hypersensitive) to losartan, hydrochlorothiazide or to any of the other ingredients in this medicine. 
• če ste alergični na (preobčutljivi za) losartan, hidroklorotiazid ali katerokoli sestavino zdravila.
Additional adverse events that have been seen with one of the individual components and may be potential adverse events with losartan potassium/ hydrochlorothiazide are the following: 
Dodatni neželeni učinki, ki so jih opazili pri eni od učinkovin in so lahko možni neželeni učinki kombinacije kalijev losartanat/hidroklorotiazid, so:
In some patients with compromised renal function who are being treated with non-steroidal antiinflammatory drugs, including selective cyclooxygenase-2 inhibitors, the co-administration of angiotensin II receptor antagonists may result in a further deterioration of renal function. 
Pri nekaterih bolnikih z oslabljenim delovanjem ledvic, ki se zdravijo z nesteroidnimi antirevmatiki, vključno s selektivnimi zaviralci ciklooksigenaze-2, lahko sočasna uporaba antagonistov receptorjev angiotenzina II povzroči nadaljnje slabšanje delovanja ledvic.
• Ringing, buzzing, roaring or clicking in the ears, 
• zvonjenje, brenčanje, bobnenje v ušesih
LIST OF EXCIPIENTS Lactose-monohydrate. 
SEZNAM POMOŽNIH SNOVI Laktoza monohidrat.
After oral use, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours the antihypertensive effect persists for up to 24 hours. 
Po peroralni uporabi se diureza začne v 2 urah, maksimum doseže v 4 urah in traja 6 do 12 ur.
Alcohol, barbiturates, narcotics or antidepressants: Potentiation of orthostatic hypotension may occur. 
Alkohol, barbiturati, narkotiki ali antidepresivi Okrepijo lahko ortostatsko hipotenzijo.
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, as it may cause intrahepatic cholestasis, and since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. 
Tiazide je treba uporabljati previdno pri bolnikih z okvaro jetrne funkcije ali napredovalo boleznijo jeter, ker lahko povzročijo intrahepatično holestazo in zaradi manjših sprememb razmerja tekočin in elektrolitov izzovejo jetrno komo.
In clinical trials, after 12 weeks of therapy with losartan 50 mg/hydrochlorothiazide 12.5 mg, trough sitting diastolic blood pressure was reduced by an average of up to 13.2 mmHg. 
V kliničnih preizkušanjih se je po 12-tedenskem zdravljenju z losartanom 50 mg/hidroklorotiazidom 12,5 mg diastolični krvni tlak, izmerjen sede tik pred naslednjim odmerkom, znižal za povprečno 13,2 mmHg.
Should exposure to Cozaar Comp have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. 
V primeru izpostavljenosti zdravilu Cozzar Comp od drugega trimesečja nosečnosti dalje se priporoča ultrazvočni pregled lobanje in delovanja ledvic.
Because of their effects on calcium metabolism, thiazides may interfere with tests for parathyroid function (see section 4.4). 
Zaradi svojih učinkov na presnovo kalcija lahko tiazidi vplivajo na izvid testov paratiroidne funkcije (glejte poglavje 4.4).
Based on pharmacokinetic data which demonstrate significantly increased plasma concentrations of losartan in cirrhotic patients, Cozaar Comp should be used with caution in patients with a history of mild to moderate hepatic impairment. 
Glede na farmakokinetične podatke, ki kažejo pomembno zvišanje plazemskih koncentracij losartana pri bolnikih s cirozo, je treba pri bolnikih, ki so kdaj imeli blago do zmerno okvaro jeter, zdravilo Cozaar Comp previdno uporabljati.
• Anaemia, red or brownish spots on the skin (sometimes especially on the feet, legs, arms and buttocks, with joint pain, swelling of the hands and feet and stomach pain), bruising, reduction in white blood cells, clotting problems and bruising, 
• anemija, rdeče ali rjavkaste lise na koži (včasih posebno na stopalih, nogah, rokah in zadnjici, z bolečinami v sklepih, otekanjem dlani in stopal in bolečinami v želodcu), modrice, zmanjšano število belih krvnih celic, motnje strjevanja krvi in modrice
Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications. 
Sočasno zdravljenje s ciklosporinom lahko poveča tveganje za hiperurikemijo in s protinom povezane zaplete.
As a consequence the observed 25% risk reduction with losartan versus atenolol brings the protective effect of losartan on stroke in the same range as for other antihypertensives. 
Zaradi tega spada opaženo 25 % zmanjšanje tveganja pri uporabi losartana v primerjavi z atenololom po zaščitnem učinku losartana proti možganski kapi v isti razpon kot učinek drugih zdravil proti hipertenziji.
When angiotensin II antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid at anti-inflammatory doses) and non-selective NSAIDs, attenuation of the antihypertensive effect may occur. 
Če se antagonisti angiotenzina II uporabljajo sočasno z nesteroidnimi antirevmatiki (NSAR) (tj. selektivnimi zaviralci COX-2, acetilsalicilno kislino v protivnetnih odmerkih in neselektivnimi NSAR-i) se lahko antihipertenzivni učinek zmanjša.
WHAT COZAAR COMP IS AND WHAT IT IS USED FOR Cozaar Comp is a combination of an angiotensin II receptor antagonist (losartan) and a diuretic (hydrochlorothiazide). 
KAJ JE ZDRAVILO COZAAR COMP IN ZA KAJ GA UPORABLJAMO Zdravilo Cozaar Comp je kombinacija antagonista angioetnzina II (losartana) in diuretika (hidroklorotiazida).
As the MAH did not submit data to demonstrate a clear population that would benefit from the FDC with regards to cardiovascular outcome, the benefit/risk of the indication in first line could be assessed and the indication is not warranted by the CHMP. 
Ker imetnik dovoljenja za promet z zdravilom ni predložil podatkov, s katerimi bi pokazal jasno opredeljeno populacijo, ki bi imela pri kardiovaskularnih rezultatih koristi od fiksne kombinacije odmerkov, razmerja med koristnimi učinki in tveganjem za indikacijo zdravljenja prve izbire ni bilo mogoče oceniti, tako da CHMP ni dal svojega jamstva.
Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites. 
Po peroralnem zaužitju se losartan dobro absorbira in je podvržen presnovi prvega prehoda, kjer nastajajo aktivni karboksikislinski presnovek in ostali neaktivni presnovki.
The usual dose of Cozaar Comp for most patients with high blood pressure is 1 tablet of Cozaar Comp 50 mg/12.5 mg per day to control blood pressure over the 24-hour period. 
Običajni odmerek zdravila Cozaar Comp za večino bolnikov z visokim krvnim tlakom je 1 tableta Cozaar Comp 50 mg /12,5 mg na dan za 24-urni nadzor krvnega tlaka.
The toxic potential of the combination of losartan/hydrochlorothiazide was evaluated in chronic toxicity studies for up to six months duration in rats and dogs after oral administration, and the changes observed in these studies with the combination were mainly produced by the losartan component. 
Toksični potencial kombinacije losartan/hidroklorotiazd so ovrednotili v študijah kronične toksičnosti, ki so trajale do šest mesecev, pri podganah in psih, ki so jim kombinacijo dajali peroralno.
The administration of the losartan/hydrochlorothiazide combination induced a decrease in the red blood cell parameters (erythrocytes, haemoglobin, haematocrit), a rise in urea-N in the serum, a decrease in heart weight (without a histological correlate) and gastrointestinal changes (mucous membrane lesions, ulcers, erosions, haemorrhages). 
Uporaba kombinacije losartan/hidroklorotiazid je povzročila zmanjšanje eritrocitnih indeksov (števila eritrocitov, hemoglobina, hematokrita) in povečanje količine N-sečnine v serumu, zmanjšanje teže srca (brez histološke povezave) in spremembe v prebavilih (lezije, ulkusi, erozije in krvavitve mukozne membrane).
If you take more Cozaar Comp than you should 
Če ste vzeli večji odmerek zdravila Cozaar Comp, kot bi smeli
The MAH did not provide data showing that those patients receiving HCTZ had a clinical advantage with respect to clinical endpoints in comparison to those not receiving HCTZ. 
Imetnik dovoljenja za promet z zdravilom ni priskrbel podatkov, ki bi kazali, da so imeli tisti bolniki, ki so prejemali tudi HCTZ, glede na klinične pokazatelje klinično prednost v primerjavi s tistimi, ki niso prejemali HCTZ.
Because of the potential for adverse effects on the nursing infant, Cozaar Comp is contraindicated during breast-feeding (see section 4.3). 
Zaradi možnih neželenih učinkov na dojenčka, je zdravilo Cozaar Comp v času dojenja kontraindicirano (glejte poglavje 4.3).
Therefore, the CHMP considered that the benefit risk for the indication Reduction in risk of cardiovascular morbidity and mortality ( or risk of stroke_) in hypertensive patients with left ventricular hypertrophy is negative and this indication is not acceptable for the FDC. 
Zaradi tega CHMP meni, da je razmerje med koristnimi učinki in tveganjem za indikacijo Zmanjšanje tveganja kardiovaskularne obolevnosti in umrljivosti (ali tveganje možganske kapi) pri hipertenzivnih bolnikih s hipertrofijo levega ventrikla negativno, tako da ta indikacija ni sprejemljiva za fiksno kombinacijo odmerkov.
2780-730 Paço d´Arcos Portugal 
2780-730 Paço d´Arcos, Portugalska
Therefore, whilst the proposed indication for losartan monotherapy was considered approvable after a majority vote by the CHMP plenum and is supported with the following wording: “reduction of risk of stroke in hypertensive patients with left ventricular hypertrophy, documented by ECG”, the following considerations apply for the FDC: 
Čeprav so na zasedanju razširjenega odbora CHMP z večino glasov zaključili, da je predlagano indikacijo za monoterapijo z losartanom mogoče odobriti in jo podpreti z besedami: „zmanjšanje tveganja kapi pri hipertenzivnih bolnikih s hipertrofijo levega ventrikla, dokumentirano z EKG“, pa je treba pri zdravljenju s fiksno kombinacijo odmerkov upoštevati naslednje:
In clinical trials with losartan potassium salt and hydrochlorothiazide, no adverse events peculiar to this combination of substances were observed. 
V kliničnih preizkušanjih s kalijevim losartanatom in hidroklorotiazidom niso opazili nobenih neželenih učinkov, značilnih za to kombinacijo.
• Others (eg bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, terfenadine, vincamine IV). 
• drugi (npr. bepridil, cisaprid, difemanil, eritromicin i.v., halofantrin, mizolastin, pentamidin, terfenadin, vincamin i.v.)
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyophathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. 
Zožanje aortne in mitralne zaklopke, obstruktivna hipertrofična kardiomiopatija Tako kot pri drugih vazodilatatorjih je posebna previdnost indicirana pri bolnikih, ki imajo zožitev aortne ali mitralne zaklopke ali obstruktivno hipertrofično kardiomiopatijo.
• if you have severely impaired liver function 
• če imate hudo okvaro jeter.
Special precautionary measures (e.g. blood tests) may be appropriate if you take potassium supplements, potassium-containing salt substitutes or potassium-sparing medicines, other diuretics (“water tablets”), some laxatives, medicines for the treatment of gout, medicines to control heart rhythm or for diabetes (oral agents or insulins). 
Posebni previdnostni ukrepi (npr. krvni testi) so potrebni, če jemljete dodatke kalija, nadomestke soli, ki vsebujejo kalij, ali zdravila, ki varčujejo kalij, druge diuretike (tablete za odvajanje vode), nekatera odvajala, zdravila za zdravljenje protina, zdravila za nadzor srčnega ritma ali sladkorne bolezni (peroralna zdravila ali insulin).
- Reduction in risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. 
- Zmanjšanje tveganja kardiovaskularne obolevnosti in umrljivosti pri hipertenzivnih bolnikih s hipertrofijo levega ventrikla
2770-192 Paço d' Arcos, Portugal 
2770-192 Paço d' Arcos, Portugalska
• Therapy resistant hypokalaemia or hypercalcaemia 
• Na zdravljenje neodzivna hipokaliemija ali hiperkalciemija.
Hypotension and Intravascular volume depletion 
Hipotenzija in zmanjšan intravaskularni volumen
Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, genotoxicity and carcinogenic potential. 
Predklinični podatki na osnovi običajnih študij splošne farmakologije, genotoksičnosti in kancerogenega potenciala ne kažejo posebnega tveganja za človeka.
• Jaundice (yellowing of the eyes and skin), inflammation of the pancreas, 
• zlatenica (porumenitev oči in kože), vnetje trebušne slinavke
Cozaar Comp may be administered with other antihypertensive agents. 
Zdravilo Cozaar Comp se lahko jemlje skupaj z drugimi antihipertenzivnimi zdravili.
Therefore, Cozaar Comp should not be given to children. 
Zato se zdravila Cozaar Comp otrokom ne sme dajati.
• Class III antiarrythmics (eg amiodarone, sotalol, dofetilide, ibutilide). 
• antiaritmiki razreda III (npr. amiodaron, sotalol, dofetilid, ibutilid)
If you experience the following, stop taking Cozaar Comp tablets and tell your doctor immediately or go to the casualty department of your nearest hospital: 
Zdravilo Cozaar Comp takoj prenehajte jemati in se posvetujte z zdravnikom ali pa takoj pojdite v najbližjo bolnišnico, če se pri vas pojavi kaj od sledečega:
Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. 
Kortikosteroidi, ACTH Potencirajo pomanjkanje elektrolitov, še posebej hipokaliemijo.
Infants whose mothers have taken Cozaar Comp should be closely observed for hypotension (see also section 4.3 and 4.4). 
Otroke, katerih matere so prejemale zdravilo Cozaar Comp, je treba pozorno spremljati zaradi možnosti pojava hipotenzije (glejte poglavji 4.3 in 4.4).
• Pain in the arms, shoulders, hips, knees or other joints, joint swelling, stiffness, muscle weakness, 
• bolečine v rokah, ramenih, kolkih, kolenih in drugih sklepih, otekanje sklepov, okorelost, šibkost mišic
SPECIAL STORAGE CONDITIONS Store in the original package. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v originalni plastenki.
How to store Cozaar Comp Further information 
Shranjevanje zdravila Cozaar Comp Dodatne informacije
• Reduction of cardiovascular morbidity and mortality (or risk of stroke) in hypertensive patients with left ventricular hypertrophy. 
• zmanjšanje kardiovaskularne obolevnosti in umrljivosti (ali tveganje možganske kapi) pri hipertenzivnih bolnikih s hipertrofijo levega ventrikla;
Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias. 
S tiazidi povzročena hipokaliemija ali hipomagneziemija lahko vzpodbudi nastanek z digitalisom povzročenih srčnih aritmij.
Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-fold and 1.7-fold greater than those seen in young male volunteers. 
Pri bolnikih z blago do zmerno alkoholno jetrno cirozo so bile plazemske koncentracije losartana oz. njegovega aktivnega presnovka po peroralni aplikaciji 5- oz. 1,7-krat večje od tistih pri mladih moških prostovoljcih.
The components of Cozaar Comp have been shown to have an additive effect on blood pressure reduction, reducing blood pressure to a greater degree than either component alone. 
Učinkovini zdravila Cozaar Comp imata aditivni učinek na zniževanje krvnega tlaka, saj ga v kombinaciji znižata bolj kot vsaka učinkovina posebej.
Losartan is a synthetically produced oral angiotensin-II receptor (type AT1) antagonist. 
Losartan je sintetičen peroralni antagonist angiotenzina II (tipa AT1).
The use of Cozaar Comp is not recommended during the first trimester of pregnancy (see section 4.4). 
Uporaba zdravila Cozaar Comp v prvem trimesečju nosečnosti ni priporočljiva (glejte poglavje 4.4).
Uncommon (affecting less than one person in 100 but more than one person in 1,000): 
Občasni (pojavijo se pri manj kot eni od 100 oseb in več kot eni od 1.000 oseb):
Cozaar Comp contains lactose. 
Zdravilo Cozaar Comp vsebuje laktozo.
As observed in studies with losartan alone, adverse foetal and neonatal effects, including renal toxicity and foetal death, occurred when pregnant rate were treated with the losartan/hydrochlorothiazide combination during late gestation and/or lactation. 
Kot so opazili v študijah s samim losartanom, so se neželeni fetalni in neonatalni učinki, ki so vključevali neželene učinke na ledvice in smrt ploda, pojavili, če so breje podgane prejemale kombinacijo losartan/hidroklorotiazid med visoko brejostjo in/ali dojenjem.
Use in patients with hepatic impairment Losartan/HCTZ is contraindicated in patients with severe hepatic impairment (see section 4.3. 
Uporaba pri bolnikih z okavaro jeter Zdravilo losartan/HCTZ je kontraindicirano pri bolnikih s hudo okvaro jeter (glejte poglavje 4.3).
Dietary salt in excessive quantities may counteract the effect of Cozaar Comp tablets. 
Velike količine soli v hrani lahko izničijo učinek zdravila Cozaar Comp.
Yellow, oval film-coated tablets marked 717 on one side and plain or scored on the other. 
Rumene, ovalne filmsko obložene tablete z oznako 717 na eni strani in z razdelilno zarezo ali brez na drugi strani.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIES OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKOV GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODIL ZA UPORABO, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
In the LIFE study an additional benefit was noted with regards to stroke for the losartan based strategy, and effects were similar with regard to MI and CV mortality, indicating that the demonstrated beneficial effect of beta-blockade on CV morbidity and mortality in general was also present for losartan. 
V študiji LIFE so za strategijo zdravljenja na podlagi losartana opazili še dodatno korist, ki se nanaša na možgansko kap, učinki pa so bili podobni glede miokardnega infarkta ali kardiovaskularne umrljivosti, kar je pomenilo, da so bili dokazani koristni učinki zaviranja beta receptorjev na kardiovaskularno obolevnost in umrljivost prisotni tudi pri losartanu.
Generally losartan causes a decrease in serum uric acid (usually <0.4 mg/dL) which was persistent in chronic therapy. 
Na splošno losartan zmanjša koncentracijo sečne kisline v serumu (običajno < 0,4 mg/dl).
Cozaar Comp therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also 5.3 'Preclinical safety data'). 
Znano je, da izpostavljenost zdravilu Cozaar Comp v drugem in tretjem trimesečju nosečnosti lahko povzroči fetotoksične učinke pri človeku (zmanjšano delovanje ledvic, oligohidramnija, zapoznela zakostenitev lobanje) in toksične učinke pri novorojenčku (odpoved ledvic, hipotenzija, hiperkalemija) (glejte poglavje 5.3).
Reproductive system and breast disorders Uncommon: Decreased libido, impotence 
Bolezni spolnih organov in dojk Občasne: zmanjšan libido, impotenca
SPECIAL STORAGE CONDITIONS Store in the original bottle. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v originalni ovojnini.
• Decreased sexual appetite, impotence, 
• zmanjšan libido, impotenca
Thiazide diuretics may increase serum calcium levels due to decreased excretion. 
Tiazidni diuretiki lahko povečajo količino kalcija v serumu zaradi njegovega zmanjšanega izločanja.